Subscribe
shutterstock_1123492958_willy_barton
Willy Barton / Shutterstock.com
18 November 2020AmericasRory O'Neill

GSK, Amgen want SCOTUS to protect genus claims

Patent law experts and pharmaceutical companies have lent their support to Merck Sharp & Dohme (MSD) in its effort to confirm the patent-eligibility of genus claims at the US Supreme Court.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
GSK claims Amgen v Sanofi decision “threatens” innovation
29 April 2021   GlaxoSmithKline has submitted an amicus brief to the Court of Appeals for the Federal Circuit claiming that the ruling on Amgen v Sanofi could “threaten incentives to invest in future discoveries.”
Americas
SCOTUS weighs future of assignor estoppel
11 January 2021   The US Supreme Court will decide whether or not to maintain a legal doctrine which stops inventors who sell their patent rights from later claiming the patents are invalid.
Americas
Fed Circuit affirms GSK $107m patent loss
20 November 2020   The US Court of Appeals for the Federal Circuit rejected GlaxoSmithKline’s challenge of a $107 million verdict which found the drugmaker had infringed a dry-powder inhaler patent.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Americas
GSK claims Amgen v Sanofi decision “threatens” innovation
29 April 2021   GlaxoSmithKline has submitted an amicus brief to the Court of Appeals for the Federal Circuit claiming that the ruling on Amgen v Sanofi could “threaten incentives to invest in future discoveries.”
Americas
SCOTUS weighs future of assignor estoppel
11 January 2021   The US Supreme Court will decide whether or not to maintain a legal doctrine which stops inventors who sell their patent rights from later claiming the patents are invalid.
Americas
Fed Circuit affirms GSK $107m patent loss
20 November 2020   The US Court of Appeals for the Federal Circuit rejected GlaxoSmithKline’s challenge of a $107 million verdict which found the drugmaker had infringed a dry-powder inhaler patent.

More on this story

Americas
GSK claims Amgen v Sanofi decision “threatens” innovation
29 April 2021   GlaxoSmithKline has submitted an amicus brief to the Court of Appeals for the Federal Circuit claiming that the ruling on Amgen v Sanofi could “threaten incentives to invest in future discoveries.”
Americas
SCOTUS weighs future of assignor estoppel
11 January 2021   The US Supreme Court will decide whether or not to maintain a legal doctrine which stops inventors who sell their patent rights from later claiming the patents are invalid.
Americas
Fed Circuit affirms GSK $107m patent loss
20 November 2020   The US Court of Appeals for the Federal Circuit rejected GlaxoSmithKline’s challenge of a $107 million verdict which found the drugmaker had infringed a dry-powder inhaler patent.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB